Barron's writer Brendan Conway
analyzes three
Fidelity funds and their tactics within regards to the the stocks of
Intercept Pharmaceuticals, which surged 582% in 2013. The funds analyzed were the
Fidelity Select Biotechnology,
Fidelity Select Healthcare, and the
Fidelity Contrafund. 
Edited by:
Tommy Fernandez
Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE